変形性関節症治療薬の世界市場機会分析

◆英語タイトル:OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2024
◆商品コード:GDHC043POA
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月27日
◆ページ数:207
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD10,995 ⇒換算¥1,231,440見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD21,990 ⇒換算¥2,462,880見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD32,985 ⇒換算¥3,694,320見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、変形性関節症治療薬の世界市場機会について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・変形性関節症の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・変形性関節症治療薬市場の現状:診断、治療概要、臨床診療、主要な医薬品
・アンメット・ニーズ及び市場機会分析
・研究開発戦略
・パイプライン分析
・パイプラインの価値分析
【レポートの概要】

OpportunityAnalyzer: Osteoarthritis – Opportunity Analysis and Forecasts to 2024

Summary

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes the bone underneath to fail. OA can occur together with other types of arthritis, such as gout or rheumatoid arthritis (RA). OA tends to affect commonly used joints such as the hands and spine as well as the weight-bearing joints such as the hips and knees. The causes of OA are not fully understood. However, genetic factors, and damage to the joints, either through repeated excessive loading and stress of a joint over time (for example, the knee joint in an obese person) or by injury (such as a break or dislocation of a finger joint) increases the risk of developing OA. There is no single test to diagnose OA. Several methods are used to diagnose OA and to rule out other problems: medical history, physical exam, X-rays, blood tests, or joint fluid analysis. The structural changes that occur with old age may not be accompanied by symptoms, which makes the estimation of the prevalence of OA difficult.

Scope

- Overview of OA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized OA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the OA therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

【レポートの目次】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 24
3.2 Symptoms 26
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities 28
4.3 Global and Historical Trends 30
4.3.1 Total Prevalence of OA – 7MM 30
4.3.2 Diagnosed Prevalence of OA – 7MM 30
4.3.3 US 31
4.3.4 5EU 31
4.3.5 Japan 32
4.4 Forecast Methodology 34
4.4.1 Sources Used 42
4.4.2 Sources Not Used 47
4.4.3 Forecast Assumptions and Methods 48
4.5 Epidemiological Forecast for OA (2014-2024) 53
4.5.1 Total Prevalent Cases 53
4.5.2 Diagnosed Prevalent Cases 70
4.5.3 Severity of Knee OA Based on KL Grades 86
4.6 Discussion 87
4.6.1 Epidemiological Forecast Insight 87
4.6.2 Limitations of the Analysis 88
4.6.3 Strengths of the Analysis 89
5 Current Treatment Options 90
5.1 Overview 90
5.2 Product Profiles – Major Therapies 92
5.2.1 NSAIDs (Numerous Branded and Generic Products) 92
5.2.2 Topical Therapies (Numerous Branded and Generic Products) 96
5.2.3 Opioids (Numerous Branded and Generic Products) 101
5.2.4 Antidepressants (Numerous Branded and Generic Products) 106
5.2.5 Intra-Articular Corticosteroid Injections (Numerous Branded and Generic Products) 108
6 Unmet Needs Assessment and Opportunity Analysis 112
6.1 Overview 112
6.2 Analgesic Drugs that Adequately Address Pain 113
6.2.1 Unmet Need 113
6.2.2 Gap Analysis 114
6.2.3 Opportunity 114
6.3 Disease-Modifying Drugs 115
6.3.1 Unmet Need 115
6.3.2 Gap Analysis 116
6.3.3 Opportunity 116
6.4 Drugs with Improved Tolerability for Use in the Elderly Patient Population 116
6.4.1 Unmet Need 116
6.4.2 Gap Analysis 117
6.4.3 Opportunity 117
6.5 Improved Implementation of Guidelines on Non-pharmaceutical Treatments 117
6.5.1 Unmet Need 117
6.5.2 Gap Analysis 118
6.5.3 Opportunity 119
6.6 Early Detection and Intervention 119
6.6.1 Unmet Need 119
6.6.2 Gap Analysis 120
6.6.3 Opportunity 120
7 Research and Development Strategies 121
7.1 Overview 121
7.2 Development of Pharmacological Treatments with Novel MOAs 121
7.3 Development of Disease-Modifying OA Drugs 122
7.4 Strategic Partnerships 123
7.5 Current Clinical Trial Design 124
7.5.1 Limitations of Patient-Reported Outcomes 125
7.5.2 Lack of Useful Subpopulations for Targeted Therapies 125
7.5.3 Lack of Consensus on DMOAD Trial Design 126
7.6 Future Clinical Trial Design 127
7.6.1 Sensitive Measurement Tools for Evaluating Joint Morphology 127
7.6.2 Developing and Qualifying Biomarkers to Enable DMOADs Development 127
7.6.3 Future Trials Need to Take into Consideration Joint Tissues Other Than Articular Cartilage 128
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Promising Drugs in Clinical Development 130
8.2.1 Ampion 130
8.2.2 NKTR-181 134
8.2.3 FX006 (Zilretta) 137
8.2.4 Anti-NGF 140
8.2.5 Invossa 147
8.2.6 Sprifermin 152
8.3 Innovative Early-Stage Approaches 156
8.3.1 Targeting Innovative Pain Signaling Pathways 158
8.3.2 Pro-inflammatory Cytokine Modulation 159
8.3.3 Growth Factor Therapy 160
8.3.4 Subchondral Bone Remodeling 160
9 Pipeline Valuation Analysis 162
9.1 Clinical Benchmarking of Key Pipeline Drugs 162
9.2 Commercial Benchmark of Key Pipeline Drugs 163
9.3 Competitive Assessment 165
9.4 Top-Line 10-Year Forecast 166
9.4.1 US 168
9.4.2 5EU 170
9.4.3 Japan 171
10 Appendix 173
10.1 Bibliography 173
10.2 Abbreviations 188
10.3 Methodology 192
10.4 Forecasting Methodology 192
10.4.1 Diagnosed OA Patients 192
10.4.2 Percent Drug-Treated Patients 193
10.4.3 Drugs Included in Each Therapeutic Class 193
10.4.4 Launch and Patent Expiry Dates 194
10.4.5 General Pricing Assumptions 194
10.4.6 Individual Drug Assumptions 195
10.4.7 Generic Erosion 201
10.4.8 Pricing of Pipeline Agents 201
10.5 Physicians and Specialists Included in this Study 203
10.6 Primary Research-Prescriber Survey 204
10.7 About the Authors 205
10.7.1 Author 205
10.7.2 Epidemiologist 205
10.8 About GlobalData 206
10.9 Disclaimer 206

1.1 List of Tables
Table 1: Etiology of OA 22
Table 2: Genes Associated with OA and Joint Development 23
Table 3: Signs and Symptoms of OA 26
Table 4: Hand, Knee, and Hip OA Severity Scoring System Using the Kellgren-Lawrence Scale 28
Table 5: Risk Factors and Comorbidities for OA 29
Table 6: Global Estimates for the Diagnosed Prevalence of OA 33
Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for Hand OA Total Prevalent Cases 35
Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of Knee OA Total Prevalent Cases 36
Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast of Hip OA Total Prevalent Cases 37
Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast of Hand OA Diagnosed Prevalent Cases 39
Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast of Knee OA Diagnosed Prevalent Cases 40
Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast of Hip OA Diagnosed Prevalent Cases 41
Table 13: 7MM, Sources of Epidemiological Data Used for the Severity* of Knee OA Based on KL Grade 42
Table 14: 7MM, Total Prevalent Cases of Hand OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 54
Table 15: 7MM, Age-Specific Total Prevalent Cases of Hand OA, Both Sexes, N (Row %), 2014 56
Table 16: 7MM, Sex-Specific Total Prevalent Cases of Hand OA, Ages ≥20 Years, N (Row %), 2014 58
Table 17: 7MM, Total Prevalent Cases of Knee OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 60
Table 18: 7MM, Age-Specific Total Prevalent Cases of Knee OA, Both Sexes, N (Row %), 2014 61
Table 19: 7MM, Sex-Specific Total Prevalent Cases of Knee OA, Ages ≥20 Years, N (Row %), 2014 63
Table 20: 7MM, Total Prevalent Cases of Hip OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 65
Table 21: 7MM, Age-Specific Total Prevalent Cases of Hip OA, Both Sexes, N (Row %), 2014 67
Table 22: 7MM, Sex-Specific Total Prevalent Cases of Hip OA, Ages ≥20 Years, N (Row %), 2014 69
Table 23: 7MM, Diagnosed Prevalent Cases of Hand OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 71
Table 24: 7MM, Age-Specific Diagnosed Prevalent Cases of Hand OA, Both Sexes, N (Row %), 2014 72
Table 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hand OA, Ages ≥20 Years, N (Row %), 2014 74
Table 26: 7MM, Diagnosed Prevalent Cases of Knee OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 76
Table 27: 7MM, Age-Specific Diagnosed Prevalent Cases of Knee OA, Both Sexes, N (Row %), 2014 77
Table 28: 7MM, Sex-Specific Diagnosed Prevalent Cases of Knee OA, Ages ≥20 Years, N (Row %), 2014 79
Table 29: 7MM, Diagnosed Prevalent Cases of Hip OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 81
Table 30: 7MM, Age-Specific Diagnosed Prevalent Cases of Hip OA, Both Sexes, N (Row %), 2014 83
Table 31: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hip OA, Ages ≥20 Years, N (Row %), 2014 85
Table 32: 7MM, Total and Diagnosed Prevalent Cases of Knee OA by Severity Based on KL Grades, Both Sexes, Ages ≥20 Years, N, 2014 87
Table 33: Overview of Leading NSAIDs for OA Treatment 93
Table 34: Efficacy of NSAIDs in OA Studies 94
Table 35: SWOT Analysis - NSAIDs, 2015 96
Table 36: Overview of the Leading Topical Therapies for OA, 2015 98
Table 37: Efficacy of Topical Therapies in OA 99
Table 38: SWOT Analysis - Topical Treatments, 2015 101
Table 39: Overview of the Leading Opioids for OA Treatment 102
Table 40: Studies Evaluating the Efficacy of Opioids in OA 103
Table 41: SWOT Analysis - Opioids, 2015 105
Table 42: Overview of the Leading Antidepressants for OA Treatment, 2015 107
Table 43: Overview of the Leading IA Corticosteroid Injectables for OA Treatment, 2015 109
Table 44: Efficacy of IA Corticosteroid Injectables in OA Studies 110
Table 45: SWOT Analysis - IA Steroid Injections in OA 111
Table 46: Unmet Needs in OA 113
Table 47: Clinical Trial Design of Key Pipeline Drugs for OA, 2015 124
Table 48: OA - Promising Drugs in Clinical Development, 2015 130
Table 49: Product Profile - Ampion 131
Table 50: Phase III (SPRING): Efficacy of Ampion in Patients with Knee OA at Week 12 132
Table 51: Phase III (SPRING Extension): Efficacy of Ampion in Patients with Moderate-to-Severe Knee OA at Week 12 132
Table 52: Ampion SWOT Analysis 133
Table 53: Product Profile - NKTR-181 135
Table 54: NKTR-181 SWOT Analysis, 2015 136
Table 55: Product Profile - FX006 137
Table 56: Phase IIb: Efficacy of FX006 in Patients with Moderate-to-Severe Knee OA at Week 12 138
Table 57: FX006 SWOT Analysis, 2015 139
Table 58: Product Profile - Tanezumab 141
Table 59: Phase III: Efficacy of Tanezumab in Patients with Knee or Hip OA 142
Table 60: Phase III: Efficacy of Tanezumab in Patients with Knee or Hip OA in Multiple Studies 143
Table 61: Tanezumab SWOT Analysis 144
Table 62: Product Profile - Fasinumab 145
Table 63: Phase II Efficacy of Fasinumab in Patients with Hip or Knee OA 146
Table 64: Fasinumab SWOT Analysis, 2015 147
Table 65: Product Profile - Invossa 149
Table 66: Phase IIb: Efficacy of Invossa in Patients with Knee OA 150
Table 67: Invossa SWOT Analysis, 2015 151
Table 68: Product Profile - Sprifermin 153
Table 69: Phase IIb: Efficacy of Sprifermin in Patients with Knee OA (at 12 Months) 154
Table 70: Sprifermin SWOT Analysis, 2015 155
Table 71: Early-Stage Pipeline Products for OA as of July 2015 157
Table 72: Clinical Benchmarking for OA 163
Table 73: Clinical Benchmarking for OA 164
Table 74: Top-Line Sales Forecast ($m) for OA, 2014-2024 166
Table 75: Key Events that Will Impact Sales for OA, 2014-2024 168
Table 76: Global OA Market - Drivers and Barriers, 2014-2024 168
Table 77: Key Launch Dates 194
Table 78: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 204

1.2 List of Figures
Figure 1: Schematic View of the Main Structures of a Healthy Joint and a Joint Affected by OA 25
Figure 2: 7MM, Total Prevalent Cases of Hand OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 54
Figure 3: 7MM, Total Prevalent Cases of Hand OA by Age Group, Both Sexes, N, 2014 57
Figure 4: 7MM, Total Prevalent Cases of Hand OA by Sex, Ages ≥20 Years, N, 2014 59
Figure 5: 7MM, Total Prevalent Cases of Knee OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 60
Figure 6: 7MM, Total Prevalent Cases of Knee OA by Age Group, Both Sexes, N, 2014 62
Figure 7: 7MM, Total Prevalent Cases of Knee OA by Sex, Ages ≥20 Years, N, 2014 64
Figure 8: 7MM, Total Prevalent Cases of Hip OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 65
Figure 9: 7MM, Total Prevalent Cases of Hip OA by Age Group, Both Sexes, N, 2014 68
Figure 10: 7MM, Total Prevalent Cases of Hip OA by Sex, Ages ≥20 Years, N, 2014 70
Figure 11: 7MM, Diagnosed Prevalent Cases of Hand OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 71
Figure 12: 7MM, Diagnosed Prevalent Cases of Hand OA by Age Group, Both Sexes, N, 2014 73
Figure 13: 7MM, Diagnosed Prevalent Cases of Hand OA by Sex, Ages ≥20 Years, N, 2014 75
Figure 14: 7MM, Diagnosed Prevalent Cases of Knee OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 76
Figure 15: 7MM, Diagnosed Prevalent Cases of Knee OA by Age Group, Both Sexes, N, 2014 78
Figure 16: 7MM, Diagnosed Prevalent Cases of Knee OA by Sex, Ages ≥20 Years, N, 2014 80
Figure 17: 7MM, Diagnosed Prevalent Cases of Hip OA, Both Sexes, Ages ≥20 Years, N, 2014-2024 81
Figure 18: 7MM, Diagnosed Prevalent Cases of Hip OA by Age Group, Both Sexes, N, 2014 84
Figure 19: 7MM, Diagnosed Prevalent Cases of Hip OA by Sex, Ages ≥20 Years, N, 2014 86
Figure 20: Stepped-Care Approach for the Treatment of OA, 2015 91
Figure 21: Competitive Assessment of OA Late-Stage Pipeline Agents, 2014-2024 165
Figure 22: Global Sales for OA by Region and Drug Class, 2014-2024 167

【レポートのキーワード】

変形性関節症

★調査レポート[変形性関節症治療薬の世界市場機会分析] (コード:GDHC043POA)販売に関する免責事項を必ずご確認ください。
★調査レポート[変形性関節症治療薬の世界市場機会分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆